Assessment of 18 F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy

Medientyp: E-Artikel

Titel: Assessment of 18 F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy

Beteiligte: Brendel, Matthias [Verfasser:in]; Barthel, Henryk [Verfasser:in]; Sauerbeck, Julia [Verfasser:in]; Nitschmann, Alexander [Verfasser:in]; Zach, Christian [Verfasser:in]; Hammes, Jochen [Verfasser:in]; Barbe, Michael T. [Verfasser:in]; Onur, Oezguer [Verfasser:in]; Jessen, Frank [Verfasser:in]; Saur, Dorothee [Verfasser:in]; Schroeter, Matthias L. [Verfasser:in]; Rumpf, Jost-Julian [Verfasser:in]; van Eimeren, Thilo [Verfasser:in]; Rullmann, Michael [Verfasser:in]; Schildan, Andreas [Verfasser:in]; Patt, Marianne [Verfasser:in]; Neumaier, Bernd [Verfasser:in]; Barret, Olivier [Verfasser:in]; Madonia, Jennifer [Verfasser:in]; Russell, David S. [Verfasser:in]; Stephens, Andrew [Verfasser:in]; Roeber, Sigrun [Verfasser:in]; Herms, Jochen [Verfasser:in]; Marek, Ken [Verfasser:in]; [...]

Erschienen: American Medical Association, 2020

Sprache: Englisch

DOI: https://doi.org/10.1001/jamaneurol.2020.2526

ISSN: 2330-9644; 0003-9942; 2168-6157; 1538-3687; 2168-6149; 0375-8540

Entstehung:

Anmerkungen: Diese Datenquelle enthält auch Bestandsnachweise, die nicht zu einem Volltext führen.

Beschreibung: Importance: Progressive supranuclear palsy (PSP) is a 4-repeat tauopathy. Region-specific tau aggregates establish the neuropathologic diagnosis of definite PSP post mortem. Future interventional trials against tau in PSP would strongly benefit from biomarkers that support diagnosis.Objective: To investigate the potential of the novel tau radiotracer 18F-PI-2620 as a biomarker in patients with clinically diagnosed PSP.Design, setting, and participants: In this cross-sectional study, participants underwent dynamic 18F-PI-2620 positron emission tomography (PET) from 0 to 60 minutes after injection at 5 different centers (3 in Germany, 1 in the US, and 1 in Australia). Patients with PSP (including those with Richardson syndrome [RS]) according to Movement Disorder Society PSP criteria were examined together with healthy controls and controls with disease. Four additionally referred individuals with PSP-RS and 2 with PSP-non-RS were excluded from final data analysis owing to incomplete dynamic PET scans. Data were collected from December 2016 to October 2019 and were analyzed from December 2018 to December 2019.Main outcomes and measures: Postmortem autoradiography was performed in independent PSP-RS and healthy control samples. By in vivo PET imaging, 18F-PI-2620 distribution volume ratios were obtained in globus pallidus internus and externus, putamen, subthalamic nucleus, substantia nigra, dorsal midbrain, dentate nucleus, dorsolateral, and medial prefrontal cortex. PET data were compared between patients with PSP and control groups and were corrected for center, age, and sex.Results: Of 60 patients with PSP, 40 (66.7%) had RS (22 men [55.0%]; mean [SD] age, 71 [6] years; mean [SD] PSP rating scale score, 38 [15]; score range, 13-71) and 20 (33.3%) had PSP-non-RS (11 men [55.0%]; mean [SD] age, 71 [9] years; mean [SD] PSP rating scale score, 24 [11]; score range, 11-41). Ten healthy controls (2 men; mean [SD] age, 67 [7] years) and 20 controls with disease (of 10 [50.0%] with Parkinson disease and multiple system ...

Zugangsstatus: Freier Zugang

Nur in Feld suchen:

Zuletzt gesuchte Begriffe: